The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease without effective therapeutics. Periostin has been reported to be elevated in IPF patients relative to controls, but its sources and mechanisms of action remain unclear. We confirm excess periostin in lungs of IPF patients and show that IPF fibroblasts produce periostin. Blood was obtained from 54 IPF patients (all but 1 with 48 wk of follow-up). We show that periostin levels predict clinical progression at 48 wk (hazard ratio = 1.47, 95% confidence interval = 1.03–2.10, P < 0.05). Monocytes and fibrocytes are sources of periostin in circulation in IPF patients. Previous studies suggest that periostin may regulate the inflammatory phase of bleomycin-induced lung injury, but periostin effects during the fibroproliferative phase of the disease are unknown. Wild-type and periostin-deficient (periostin−/−) mice were anesthetized and challenged with bleomycin. Wild-type mice were injected with bleomycin and then treated with OC-20 Ab (which blocks periostin and integrin interactions) or control Ab during the fibroproliferative phase of disease, and fibrosis and survival were assessed. Periostin expression was upregulated quickly after treatment with bleomycin and remained elevated. Periostin−/−mice were protected from bleomycin-induced fibrosis. Instillation of OC-20 during the fibroproliferative phase improved survival and limited collagen deposition. Chimeric mouse studies suggest that hematopoietic and structural sources of periostin contribute to lung fibrogenesis. Periostin was upregulated by transforming growth factor-β in lung mesenchymal cells, and periostin promoted extracellular matrix deposition, mesenchymal cell proliferation, and wound closure. Thus periostin plays a vital role in late stages of pulmonary fibrosis and is a potential biomarker for disease progression and a target for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationSime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Horiuchi, K., Amizuka, N., Takeshita, S., Takamatsu, H., Katsuura, M., Ozawa, H., Toyama, Y., Bonewald, L. F., & Kudo, A. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.7.1239 · Cited by 975
Murine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Takayama, G., Arima, K., Kanaji, T., Toda, S., Tanaka, H., Shoji, S., McKenzie, A. N. J., Nagai, H., Hotokebuchi, T., & Izuhara, K. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.046 · Cited by 674
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622 · cited 1×
“We have also demonstrated that some IPF patients experience acute deteriorations and mortality that are independent of change in pulmonary physiology (7, 22).”
BackgroundSelf-citation
Cited by
Deng, C.-C., Hu, Y.-F., Zhu, D.-H., Cheng, Q., Gu, J.-J., Feng, Q.-L., Zhang, L.-X., Xu, Y.-P., Wang, D., Rong, Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24110-y · Cited by 487
The role of periostin in tissue remodeling across health and disease
Conway, S. J., Izuhara, K., Kudo, Y., Litvin, J., Markwald, R., Ouyang, G., Arron, J. R., Holweg, C. T. J., & Kudo, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1494-y · Cited by 421
Han, M. K., Zhou, Y., Murray, S., Tayob, N., Noth, I., Lama, V. N., Moore, B. B., White, E. S., Flaherty, K. R., Huffnagle, G. B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70069-4 · Cited by 411
Self-citationMulti-organ proteomic landscape of COVID-19 autopsies
Nie, X., Qian, L., Sun, R., Huang, B., Dong, X., Xiao, Q., Zhang, Q., Lu, T., Yue, L., Chen, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.004 · Cited by 408
IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis
Hams, E., Armstrong, M. E., Barlow, J. L., Saunders, S. P., Schwartz, C., Cooke, G., Fahy, R. J., Crotty, T. B., Hirani, N., Flynn, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315854111 · Cited by 376
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis
O’Dwyer, D. N., Ashley, S. L., Gurczynski, S. J., Xia, M., Wilke, C., Falkowski, N. R., Norman, K. C., Arnold, K. B., Huffnagle, G. B., Salisbury, M. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1650oc · Cited by 366
Self-citationMladěnka, P., Macáková, K., Kujovská Krčmová, L., Javorská, L., Mrštná, K., Carazo, A., Protti, M., Remião, F., Nováková, L., & collaborators, T. O. R. A. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuab061 · Cited by 262
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142
Self-citationBiomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Matrix biomechanics and dynamics in pulmonary fibrosis
Haak, A. J., Tan, Q., & Tschumperlin, D. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.004 · Cited by 95
Categorization of lung mesenchymal cells in development and fibrosis
Liu, X., Rowan, S. C., Liang, J., Yao, C., Huang, G., Deng, N., Xie, T., Wu, D., Wang, Y., Burman, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102551 · Cited by 91
Biomarker signatures for progressive idiopathic pulmonary fibrosis
Clynick, B., Corte, T. J., Jo, H. E., Stewart, I., Glaspole, I. N., Grainge, C., Maher, T. M., Navaratnam, V., Hubbard, R., Hopkins, P. M. A., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01181-2021 · Cited by 86
Nikitopoulou, I., Manitsopoulos, N., Kotanidou, A., Tian, X., Petrovic, A., Magkou, C., Ninou, I., Aidinis, V., Schermuly, R. T., Kosanovic, D., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019881954 · Cited by 44
Wan, H., Huang, X., Cong, P., He, M., Chen, A., Wu, T., Dai, D., Li, W., Gao, X., Tian, L., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.711239 · Cited by 33
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
Metadata
- Authors
- Naik, P. K., Bozyk, P. D., Bentley, J. K., Popova, A. P., Birch, C. M., Wilke, C. A., Fry, C. D., White, E. S., Sisson, T. H., Tayob, N., Carnemolla, B., Orecchia, P., Flaherty, K. R., Hershenson, M. B., Murray, S., Martinez, F. J., Moore, B. B., & the COMET Investigators
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2012-12-15
- Volume
- 303
- Issue
- 12
- Pages
- L1046-L1056
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2146225176
- Cited by
- 260
- References
- 37
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.